The first real-world study of its kind revealed that rivaroxaban, marketed as Xarelto, can reduce the risk of stroke and major bleeding in patients with atrial fibrillation (AF) – a group that is five times more likely to suffer a stroke compared to the general population.
With the exception of perhaps stroke neurologists, who see the devastating effects of stroke every day, many other physicians let fear guide their anticoagulation treatment decisions, according to the experts.
In atrial fibrillation, aspirin could double a patient’s risk for bleeding. And yet, it is still used all the time. Hear the experts discuss the importance of using a “real” anticoagulant for patients who need to be anticoagulated.
The MANTRA-PAF trial, A study looking at a treatment for paroxysmal atrial fibrillation reached its five year follow-up mark and the results were shared at the recent European Society of Cardiology Congress to see whether surgical or pharmaceutical treatment was better for patients.
While the treatment of atrial fibrillation has made many advancements in recent years there is still much more work to be done. As with other areas of medicine this includes individualized approaches to care.